HIV and Covid 19 Coinfection, A Local Perspective: A Retrospective Study from Qatar
暂无分享,去创建一个
[1] R. Iachan,et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[2] Reed J. D. Sorensen,et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.
[3] K. Telle,et al. Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households. , 2022, JAMA.
[4] C. Scagnolari,et al. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report: Erratum , 2020, Medicine.
[5] C. Agrati,et al. COVID‐19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS‐CoV‐2 , 2020, Journal of medical virology.
[6] C. Scagnolari,et al. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection , 2020, Medicine.
[7] T. Kuno,et al. Prognosis of coronavirus disease 2019 (COVID‐19) in patients with HIV infection in New York City , 2020, HIV medicine.
[8] K. Bhaskaran,et al. HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform , 2020, medRxiv.
[9] B. Woodward,et al. Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review , 2020, HIV medicine.
[10] M. Peluso,et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus , 2020, The Journal of Infectious Diseases.
[11] Jessica K De Freitas,et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[12] W. Mcfarland,et al. COVID-19 Among People Living with HIV: A Systematic Review , 2020, AIDS and Behavior.
[13] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.
[14] R. López-Vélez,et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.
[15] A. Okoh,et al. COVID-19 Pneumonia in Patients With HIV: A Case Series , 2020, Journal of acquired immune deficiency syndromes.
[16] M. Carrington,et al. Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2 , 2020, bioRxiv.
[17] Maomao Wang,et al. One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4+ T-cell count , 2020, International Journal of Infectious Diseases.
[18] Felipe García,et al. COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.
[19] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[20] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[21] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[22] J. Aberg. Aging, inflammation, and HIV infection. , 2012, Topics in antiviral medicine.
[23] P. Boudes. HIV infection in the elderly. , 1991, Comprehensive therapy.
[24] N. Michael,et al. Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.